Janice Brown
Academic Appointments
- Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Blood and Marrow Transplant Program 300 Pasteur Drive H0101, MC 5623 Stanford, CA 94305 Tel Work (650) 723-0822 Fax (650) 725-8950
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Blood and Marrow Transplant
- Blood and Marrow Transplantation
- Blood and Marrow Transplantation / Infectious Diseases
- Infectious Disease
Professional Education
| Fellowship: | Stanford University School of Medicine CA (1993) |
| Residency: | Stanford University School of Medicine CA (1990) |
| Internship: | Stanford University School of Medicine CA (1988) |
| Medical Education: | University of Virginia VA (1987) |
| BA: | Stanford University, Biological Sciences (1981) |
| MD: | University of Virginia, Hypoxemic myocardial injury (1987) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Clinical Trials
- Not Recruiting Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
- Recruiting Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
- Recruiting Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
- Not Recruiting A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001 AM4)
- Recruiting Post T-plant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidate Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Publications
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012; (4): 581-8
- Combined effects of interleukin-7 and stem cell factor administration on lymphopoiesis after murine bone marrow transplantation. Biol Blood Marrow Transplant. 2011; (1): 48-60
- Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen. Biol Blood Marrow Transplant. 2011; (5): 693-702
- Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant. 2011; (2): 192-9
- Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients. Biol Blood Marrow Transplant. 2011; (2): 259-64
- A 39-year-old woman with lupus, myositis, and a recalcitrant vasculopathy. Arthritis Care Res (Hoboken). 2010; (9): 1351-6
Help